United States Patent Office Patented June 21, 1966 1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany). -
Opinion on Salicylic Acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019
SCCS/1601/18 Final Opinion Corrigendum of 20-21 June 2019 Scientific Committee on Consumer Safety SCCS OPINION ON salicylic acid (CAS 69-72-7) Submission I The SCCS adopted the final Opinion by written procedure on 21 December 2018 Corrigendum of 20-21 June 2019 SCCS/1601/18 Final Opinion Opinion on salicylic acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019 ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final Opinion The SCCS members: Dr U. Bernauer Dr L. Bodin Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri (Rapporteur) Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven External experts: Dr A. Simonnard Dr A. Koutsodimou Prof. W. Uter The additional contribution of the following external expert is gratefully acknowledged: Dr. N. von Goetz All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 10 September until 14 November 2018). Comments received during this time were considered by the SCCS. For this Opinion, comments received resulted in the following main changes: sections 3.3.1.1. -
Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan -
Alphabetical Listing of ATC Drugs & Codes
Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04 -
United States Patent Office Patented May 31, 1966 1
3,253,990 United States Patent Office Patented May 31, 1966 1. 2 3,253,990 rapid onset of analgetic action. N-methyl glucammo N-METHYL GLUCAMMONUM SALCYLATE nium salicylate has important advantages over the numer AND USES THEREFOR ous known salicylates which have been recommended for Hans Suter, Schaffhausen, Switzerland, assignor to Mundi pharma AG, Rheinfelden, Switzerland, a corporation of clinical use. It is more stable in aqueous solution than Switzerland the commonly used acetylated salicylic acid (aspirin), and No Drawing. Filled Dec. 27, 1962, Ser. No. 247,491 it does not cause the gastrointestinal disturbances which Claims priority, application Switzerland, Jan. 17, i962, have been reported after the administration of aspirin and 48/62 other conventional salicylate drugs. N-methyl glucam 11. Claims. (C. 167-64) monium salicylate is rapidly absorbed into the blood 0. stream and does not interfere with the acid-base balance The present invention concerns a new and novel salicy of the blood nor does it contribute large quantities of late compound, the process for its preparation and the Sodium ion to affect the water retention of the tissues. method of use to achieve an elevated blood level of N-methylglucammonium salicylate is a white crystalline salicylate ion. In particular, it is concerned with N-meth solid, melting at 100° C. and is stable under the usual yl glucammonium salicylate, the process for its prepara 5 conditions of storage. It does not have the hygroscopic tion and the use of the said compound to achieve an properties of other substituted salts of salicylic acid and, elevated blood level of salicylate ion. -
Amended Safety Assessment of Salicylic Acid and Salicylates As Used in Cosmetics
Amended Safety Assessment of Salicylic Acid and Salicylates as Used in Cosmetics Status: Final Amended Report Release Date: June 5, 2019 Panel Date: April 8-9, 2019 The 2019 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This report was prepared by Wilbur Johnson, Jr., M.S., Senior Scientific Analyst, and Jinqiu Zhu, Ph.D., Toxicologist. © Cosmetic Ingredient Review 1620 L STREET, NW, SUITE 1200 ◊ WASHINGTON, DC 20036-4702 ◊ PH 202.331.0651 ◊ FAX 202.331.0088 ◊ [email protected] ABSTRACT: The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) reviewed the safety of Salicylic Acid and 17 salicylates; 15 of these ingredients were previously reviewed by the Panel, and 3 are reviewed herein for the first time. Some of the reported functions in cosmetics for ingredients in this group are hair and skin conditioning agents, and, less frequently, preservatives and fragrance ingredients. Upon review of relevant new data, including frequency and concentration of use, and consideration of data from the previous CIR report, the Panel concluded that Salicylic Acid and 17 salicylate ingredients are safe in cosmetics in the present practices of use and concentration described in the safety assessment when formulated to be non-irritating and non-sensitizing, which may be based on a quantitative risk assessment (QRA). -
Salicylate Toxicity
Clinical Toxicology (2007) 45, 95–131 Copyright © American Association of Poison Control Centers ISSN: 1556-3650 print / 1556-9519 online DOI: 10.1080/15563650600907140 PRACTICELCLT GUIDELINE Salicylate poisoning: An evidence-based consensus guideline for out-of-hospital management* PETEROut-Of-Hospital Management of Salicylate A. Poisoning CHYKA, PHARM.D., ANDREW R. ERDMAN, M.D., GWENN CHRISTIANSON, M.S.N., PAUL M. WAX, M.D., LISA L. BOOZE, PHARM.D., ANTHONY S. MANOGUERRA, PHARM.D., E. MARTIN CARAVATI, M.D., M.P.H., LEWIS S. NELSON, M.D., KENT R. OLSON, M.D., DANIEL J. COBAUGH, PHARM.D., ELIZABETH J. SCHARMAN, PHARM.D., ALAN D. WOOLF, M.D., M.P.H., and WILLIAM G. TROUTMAN, PHARM.D. American Association of Poison Control Centers, Washington, District of Columbia, USA A review of U.S. poison center data for 2004 showed over 40,000 exposures to salicylate-containing products. A guideline that determines the conditions for emergency department referral and pre-hospital care could potentially optimize patient outcome, avoid unnecessary emergency department visits, reduce health care costs, and reduce life disruption for patients and caregivers. An evidence-based expert consensus process was used to create the guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the lead author. The entire panel discussed and refined the guideline before distribution to secondary reviewers for comment. The panel then made changes based on the secondary review comments. The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial out-of-hospital management of patients with a suspected exposure to salicylates by 1) describing the process by which a specialist in poison information should evaluate an exposure to salicylates, 2) identifying the key decision elements in managing cases of salicylate exposure, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. -
Lääkeluettelon Aineet, Liite 1., Luonnos Ämnena I
LÄÄKELUETTELON AINEET, LIITE 1., LUONNOS 1 ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1., UTKAST uusi x Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi uusi x Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Diklooribentsyyli- 2,4-Dichlorbenzyl-alcoholum alkoholi 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- aminophenolum 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol 4-Hydroxyvaleratum 4-Hydroksivaleraatti 4-Hydroxivalerat 4-Hydroxyvalerate 5-methoxy-alpha- methyltryptaminum (5-MeO- 5-metoksi-alfa- 5-metoxi-alfa- 5-methoxy-alfa- AMT) metyylitryptamiini metyltryptamin methyltryptamine 5-methoxy-N,N-methyl- isopropyltryptaminum (5-MeO- 5-metoksi-N,N-metyyli- 5-metoxi-N,N-metyl- 5-methoxy-N,N-methyl- MIPT) isopropyylitryptamiini isopropyltryptamin isopropyltryptamine Abacavirum Abakaviiri Abakavir Abacavir x Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acenocoumarolum Asenokumaroli -
WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD. -
Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
LUONNOS 5.12.2018 Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä 15. päivänä maaliskuuta 2019 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § vallisten valmisteiden ja erityislupavalmis- Luettelon tarkoitus teiden vaikuttavia lääkeaineita. Liitteessä 1 on lueteltu ainoastaan lääkeai- Tämä päätös sisältää luettelon Suomessa neet. Lääkeaineiden suoloja ja estereitä ei ole lääkkeellisessä käytössä olevista aineista ja lueteltu. Lääkeaineet ovat valmisteessa suo- rohdoksista. Lääkeluettelo laaditaan ottaen lamuodossa teknisen käsiteltävyyden vuoksi. huomioon lääkelain 3 §:n ja 5 §:n säännök- Lääkeaine ja sen suolamuoto ovat biologises- set. ti samanarvoisia. Lääkkeellä tarkoitetaan valmistetta tai ai- Liitteen 1 A aineet ovat lääkeaineanalogeja netta, jonka tarkoituksena on sisäisesti tai ja prohormoneja. Kaikki liitteen 1 A aineet ulkoisesti käytettynä parantaa, lievittää tai rinnastetaan aina vaikutuksen perusteella ehkäistä sairautta tai sen oireita ihmisessä tai ainoastaan lääkemääräyksellä toimitettaviin eläimessä. Lääkkeeksi katsotaan myös sisäi- lääkkeisiin. sesti tai ulkoisesti käytettävä aine tai aineiden yhdistelmä, jota voidaan käyttää ihmisen tai 2 § eläimen elintoimintojen palauttamiseksi, Lääkkeitä ovat korjaamiseksi tai muuttamiseksi farmakolo- 1) tämän päätöksen liitteessä 1 luetellut ai- gisen, immunologisen tai metabolisen vaiku- neet, niiden suolat -
Atc Index 2010
ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine -
Risk Profile
RISK PROFILE Methyl salicylate C A S N o . 1 1 9 - 36- 8 Date of reporting 10.12.201 2 Content of document 1. Identification of substance ...................................................................... p. 1 2. Uses and origin ................................................................................... p. 2 3. Regulation ................................................................................................ p. 4 4. Relevant toxicity studies ....................................................................... p. 4 5. Exposure estimates and critical NOAEL/NOEL .............................................. p. 9 6. Other sources of exposure than cosmetic products ................................. p. 11 7. Assessment ................................................................................................. p. 13 8. Conclusion ................................................................................................. p. 14 9. References ................................................................................................. p. 15 10. Annexes ................................................................................................. p. 18 1. Identification of substance Chemical name (IUPAC): 2-Hydroxy-benzoic acid methyl ester INCI Methyl salicylate Synonyms Hydroxybenzoic acid, Oil of wintergreen (ca. 98% methyl salicylate) CAS No. 119-36-8 EINECS No. 204-317-7 Molecular formula C8H8O3 Chemical structure Molecular weight 152.15 Risk profile Methyl salicylate Page 1 of 19 Version date: 23Oct2012